Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

DHX9 inhibitor ATX-559

An orally bioavailable inhibitor of the protein RNA helicase A (DHX9; DDX9; RHA), with potential antineoplastic activity. Upon oral administration, DHX9 inhibitor ATX-559 targets, binds to and inhibits DHX9. This may cause genomic instability and may lead to DNA replication stress and DNA damage, and may induce apoptosis in certain vulnerable cancer cells. DHX9, a multi-functional RNA helicase, is involved in the maintenance of genomic stability by resolving DNA/RNA secondary structures that may lead to DNA replication stress and DNA damage in certain molecularly defined cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:helicase DHX9 inhibitor ATX-559
RNA helicase A inhibitor ATX-559
Code name:ATX 559
ATX-559
ATX559
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search